MétaCan
Menu
Back to cohort
Record W4416549169 · doi:10.1016/j.pnpbp.2025.111565

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial

2025· article· en· W4416549169 on OpenAlexafffund
Danica E. Johnson, Shakila Meshkat, Erica Kaczmarek, Jennifer S. Rabin, Ryan M. Brudner, Noah Chisamore, Zoe Doyle, Jordan Bawks, Jeremy Riva-Cambrin, Rodrigo B. Mansur, Orly Lipsitz, Roger S McIntyre, Krista L. Lanctôt, Joshua D. Rosenblat

Bibliographic record

VenueProgress in Neuro-Psychopharmacology and Biological Psychiatry · 2025
Typearticle
Languageen
FieldPsychology
TopicPsychedelics and Drug Studies
Canadian institutionsSt. Joseph’s Healthcare HamiltonSunnybrook Health Science CentreCanadian Transplant AssociationUniversity of Toronto
FundersGlobal Alliance for Chronic DiseasesCanadian Psychiatric AssociationNational Natural Science Foundation of ChinaCanadian Cancer SocietyPhysicians' Services Incorporated FoundationLife Sciences, University of California, Los AngelesBrain and Cognition Discovery FoundationUsona InstituteAbbVieCanadian Institutes of Health ResearchBoehringer IngelheimMilken Institute
KeywordsCognitionMoodTest (biology)Schizophrenia (object-oriented programming)Randomized controlled trialExecutive functionsCognitive remediation therapy

Abstract

fetched live from OpenAlex

BACKGROUND: Cognitive difficulties within treatment-resistant unipolar and bipolar depression (TRD; TRBD) often do not improve with conventional pharmacotherapies. Psilocybin-assisted psychotherapy (PAP) has shown promise as a novel intervention for TRD; however, few studies have assessed its effects on cognition in this population. METHODS: This retrospective post hoc analysis included 26 adults with TRD or TRBD from an open-label trial of PAP. Cognition was assessed with the Digit Symbol Substitution Test (DSST) and Trail Making Test Part A and B (TMT-A/B) at baseline, one-day, and two-weeks post-treatment. Linear mixed models (LMMs) evaluated change over time, and reliable change indices (RCIs) with binomial tests assessed whether the proportion of participants showing meaningful improvement exceeded chance. RESULTS: Significant improvements were observed on all cognitive measures over time (all p < .05). After adjusting for depressive symptoms, gains on the TMT-A (p < .001), TMT-B (p < .001), and TMTB - A (p = .005) remained significant. In contrast, DSST improvements were attenuated (p = .069). RCIs showed that 4.2 %-12.5 % of participants achieved meaningful improvement, but these rates did not significantly exceed chance expectations. CONCLUSION: PAP was associated with modest, short-term improvements in performance on measures of processing speed and executive function among individuals with TRD. While these changes appeared independent of mood, they did not consistently exceed expected practice effects. These findings highlight the need for adequately powered, controlled trials to clarify whether observed cognitive changes reflect genuine procognitive effects of psilocybin or are attributable to non-specific influences such as test familiarity or concurrent mood improvements.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.006
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0050.004
Bibliometrics0.0010.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.032
GPT teacher head0.398
Teacher spread0.366 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueProgress in Neuro-Psychopharmacology and Biological PsychiatrySame topicPsychedelics and Drug StudiesFrench-language works237,207